ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2550

Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome

Esther Rodriguez-Almaraz1, Elena Gonzalo-Gil2, Ignacio Herráiz3, Paula I Gómez-Arriaga3, Paloma Vallejo3, Elena A López-Jiménez4, María Galindo Izquierdo1 and Alberto Galindo Izquierdo3, 1Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 2Grupo de Investigación en Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 3Fetal Medicine Unit, Department of Obstetrics and Gynecology. Hospital Universitario 12 de Octubre., Madrid, Spain, 4Department of Biochemistry. Hospital Universitario 12 de Octubre., Madrid, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome, pregnancy and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Patients with systemic lupus erythematosus (SLE) have an increased risk of preeclampsia (PE), which can be confused with lupus nephritis. Our objective was to evaluate the behaviour of mean pulsatility index in the uterine arteries (mPI-UtA), sFlt-1/PlGF ratio and endoglin levels in pregnant women with SLE and/or antiphospholipd syndrome (APS).

Methods:

Pregnant women with SLE and/or APS attending our high-risk pregnancy unit were consecutively included. Clinical, analytical and sonographic evaluations were conducted at baseline, at different weeks (wk) of gestational age (10-13, 22, 28, 32), at delivery and postpartum. We collected demographic data, information regarding cardiovascular risk factors and toxic habits, the underlying disease, obstetrical history, last SLE flare, previous and current treatments, as well as usual blood tests including complement and a-dsDNA antibodies levels. Levels of sFlt-1, PlGF, and maternal serum endoglin were quantified by ELISA.  PE and its severity were diagnosed according with the ISSSHP definition. Intrauterine growth restriction (IUGR) was defined as a small for gestational age newborn together with a Doppler PI in the umbilical artery above the 95th percentile.

Results:

34 consecutive patients were recruited, of whom 29 had SLE (4 with secondary APS), 3 had primary APS and 2 had antiphospholipid antibodies but without clinical criteria for APS. Five patients have not delivered at the time of writing and we missed 1 patient in the follow-up. Ten patients (36%) suffered an early pregnancy loss (<12 wks), being most frequent among patients with previous APS diagnosis (p =0.03), high blood pressure (p =0.01), arterial thrombosis related to APS (p =0.03), and the presence of lupus anticoagulant (p =0.004). In uneventful pregnancies the values of the studied markers were within normal limits for the gestational age throughout pregnancy. One SLE patient (5.6%) had mild PE after 32 wk together with IUGR. We observed a relationship between IUGR and higher SLEDAI both before and throughout pregnancy (baseline, p =0.01; 10-13 wks, p =0.04; 22 wk, p =0.02; 28 wk, p = 0.05; 32 wk, p =0.01). IUGR was also associated with higher mPI-UtA at 22 wk (p =0.05). Endoglin levels (14.6 ng/ml vs <7.9, 26.9 vs <7.2, 49 vs <13.6, at 22 wk, 28 wk and 32 wk, respectively) and ratio curve sFlt1/PlGF (17 vs 14.8, 36.6 vs 16.9, 170.7 vs 86.4 at 22 wk, 28 wk and 32 wk, respectively) behaved abnormal in this case. Among remaining patients, 1 patient with SLE (5.6%) developed HBP before delivery, 1 SLE patient had premature rupture of membranes at term, and 3 SLE patients had a preterm delivery at 28, 32 and 36 wks, respectively. 12 patients (67%) had a mild exacerbation of SLE, and only 1 (8%) had moderate activity requiring high doses of corticosteroids and azathioprine.

Conclusion:

Our preliminary results indicate that mPI-UtA, sFlt1/PlGF ratio and endoglin levels behave in patients with SLE and/or APS essentially as in the general population. Moreover, these markers may be useful to predict the onset of PE in women with SLE and to make the differential diagnosis between PE and an episode of lupus activity.


Disclosure:

E. Rodriguez-Almaraz,
None;

E. Gonzalo-Gil,
None;

I. Herráiz,
None;

P. I. Gómez-Arriaga,
None;

P. Vallejo,
None;

E. A. López-Jiménez,
None;

M. Galindo Izquierdo,
None;

A. Galindo Izquierdo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-markers-of-preeclampsia-during-pregnancy-in-patients-with-systemic-erithematosus-lupus-and-or-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology